Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer

Abstract

Semuloparin reduces the incidence of thromboembolic events in patients receiving chemotherapy for cancer, with no apparent increase in major bleeding. (Funded by Sanofi; ClinicalTrials.gov number, NCT00694382.).